Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ss applicable to common stock of $2.7 million, or ($0.17) per share, basic and diluted, compared with a net loss of $3.7 million or ($0.29) per share for the same period in 2011. For the full year 2012, the Company reported a net loss applicable to common stock of $10.9 million, or ($0.72) per share, basic and diluted, compared with a net loss of $12.7 million, or $(1.06) per share in 2011. The full year 2012 results include $0.2 million of other income as well as $1.2 million of non-cash expense related to dividends and accretion on the preferred stock compared with $1.8 million in 2011. The weighted average number of shares used to calculate loss per share increased for the 2012 periods compared to the 2011 periods due primarily to the March 2012 offering of 2.7 million common shares as well as the payment of dividends in common stock.

Research and development expense for the fourth quarter of 2012 was $1.0 million, compared with $0.9 million for the same period in 2011. Research and development expense for the full year 2012, was $4.5 million, compared with $3.6 million in 2011. The increase for the fourth quarter and the year-over-year expenses is due primarily to increased pre-clinical activity in our fibrosis program as we prepared to file an IND in January 2013 and begin a Phase I clinical trial, offset by decreased expenses related to stock-based compensation.General and administrative expense for the fourth quarter of 2012 was $1.4 million, compared with $2.5 million for the same period in 2011. General and administrative expense for the full year 2012 was $5.4 million as compared to $6.9 million for 2011. The decrease for the fourth quarter and full year 2012 is due primarily to the recognition of a $1.0 million payment related to a separation agreement during the fourth quarter of 2011. Additionally, the decrease in expense for the fourth quarter and full year 2012 is due primarily to overall decreased business development costs as we decreased wor
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014 Cord Blood Registry® (CBR®) announces ... Annual World Stem Cell Summit, the largest global meeting of ... Stem Cell Summit will be held December 3-5 at the ... The World Stem Cell Summit ... and therapies, convening the most prominent figures in the field ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring ... professor in the Regulatory Biology Laboratory at the Salk Institute, ... to an “off switch” for drug resistance in cancer. , ... research is making a global impact in the fight against ... host Cheryl K. Goodman, CEO of Social Global Mobile LLC, ...
(Date:11/18/2014)... November 18, 2014 2014 ... Industry is professional and in-depth report on ... basic information, including its definition, characterization, application, ... outline. This exploration covers the worldwide business ... industry examination covering macroeconomic environment & financial ...
(Date:11/18/2014)... -- Great Basin Scientific, Inc. (NASDAQ: GBSN ), a ... a conference call and webcast to provide an update on ... at 4:30 pm EST time. "We are pleased ... IPO and would like to provide our investors with an ... , President and Chief Executive Officer of Great Basin Scientific. ...
Breaking Biology Technology:Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3Great Basin Scientific Announces Conference Call to Provide Update on Corporate Progress 2
... Wis. The biotechnology firm OpGen hopes its new CEO ... said on Monday. R.H. Joseph Shaw is the former CEO of ... comes to OpGen with a good history of raising serious funds, ... David Schwartz , one of OpGens founders and a professor ...
... implement all of the great ideas floating around Wisconsin on ... what that economy will look like in the year 2020. ... needs to be accomplished. Capping the growth of government, regulatory ... linking the colleges and universities with the business community, finishing ...
... founding partner in communications firm Rathmann-Fronbery LLC . ... two clients. , ,Wisconsin manufacturers are relying more ... creating a demand for Asian management talent in numerous ... costly, but technology such as videoconferencing is being employed ...
Cached Biology Technology:OpGen recruits CEO to further gene-mapping business 2Wisconsin 2020: A vision from a state senator 2Wisconsin 2020: A vision from a state senator 3Lack of broadband hamstrings international videoconferencing 2Lack of broadband hamstrings international videoconferencing 3
(Date:11/7/2014)... SPRINGS, Florida , November 6, 2014 ... secure authentication for better mobile security revolutionizing online transactions.  Companies ... ), Alibaba Holdings Ltd. (NYSE: BABA ), Google ... MSFT ), eBay Inc. (NASDAQ: EBAY ) ... NXTD and NXTDW), a biometric authentication company ...
(Date:11/6/2014)... 2014 - Insilico Medicine, Inc, a Baltimore-based bioinformatics ... related diseases announced a research collaboration with the ... Oncology, Inc (OTC: CSBR). , "There are many ... but Champions Oncology,s TumorGraft technology is unique in ... regimen experimentally generating vast amounts of valuable data. ...
(Date:11/4/2014)... of Utah engineers developed the first room-temperature fuel cell ... without needing to ignite the fuel. These new fuel ... power and sensors. , A study of the new ... journal ACS Catalysis . , Fuel cells convert ... fuel and an oxygen-rich source such as air. If ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Jet-fueled electricity at room temperature 2
... the future of their health? On May 27, researchers ... National Cancer Institute (NCI), along with Group Health Cooperative in ... that question during the one-day symposium "Multiplex Initiative: Implications for ... symposium. It will be held from 7:30 a.m. 3:30 ...
... Ariz. May 12, 2010 Dr. James Bogenberger ... the American Cancer Society to research acute myeloid leukemia ... myeloid leukemia (AML), the most common and deadliest acute ... the body,s white blood cells that battle infections. ...
... tool that relies on magnetic fields and radio ... soft tissuesmay soon become even more useful. ... has unveiled the first "phantom" for calibrating MRI ... prototype, named Phannie, was developed in collaboration with ...
Cached Biology News:Symposium: Implications for the future of personalize medicine 2Symposium: Implications for the future of personalize medicine 3TGen researcher awarded American Cancer Society fellowship 2Meet Phannie, NIST's standard 'phantom' for calibrating MRI machines 2
... Metalloproteinase-2, Hinge Region By immunoblotting the antibody ... It reacts with free MMP-2 or MMP-2 ... buffered aqueous glycerol solution Solution in ... containing 50% glycerol and 15 mM sodium ...
... This CLS number is ... created to easily match ... showing no availability yet, ... old Sigma-Aldrich number (Z71,381-3) ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z37,208-0) ... assistance. Mfr Desig: Corning ...
... Description: 100 g ... 70 kDa YAP from Human/mouse/rat samples. ... Research Focus: ... -20C Shipping ...
Biology Products: